LEADER 01286oam  2200409 a 450 
001 9910708127603321
005 20130206163332.0
035   $a(CKB)4970000000040645
035   $a(OCoLC)823391481
035   $a(EXLCZ)994970000000040645
100   $a20130105d2012      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aMedicare$b[electronic resource] $ehigh-expenditure Part B drugs /$f[James Cosgrove]
210  1$aWashington, DC :$cU.S. Govt. Accountability Office,$d[2012]
215   $a1 online resource (29 pages) $ccolor illustrations
300   $aTitle from title screen (viewed Dec. 31, 2012).
300   $a"October 12, 2012."
300   $a"GAO-13-46R."
320   $aIncludes bibliographical references.
517   $aMedicare
606   $aMedicare$xEconomic aspects
606   $aDrugs$zUnited States$xCosts
615  0$aMedicare$xEconomic aspects.
615  0$aDrugs$xCosts.
700   $aCosgrove$b James C$01395889
712 02$aUnited States.$bGovernment Accountability Office.
801  0$bVVK
801  1$bVVK
801  2$bGPO
906   $aDOCUMENT
912   $a9910708127603321
996   $aMedicare$93462118
997   $aUNINA